Mergers & acquisitions
Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholders.
Bristol-Myers Squibb and Celgene Corporation are strongly urging shareholders to submit their proxy votes as quickly as possible whether they plan to attend the April 12, 2019 Special Meeting or not. The meeting is when the official vote on whether Bristol-Myers Squibb will buy Celgene will take place.
San Diego-based Pacira Pharmaceuticals, a specialty pharmaceutical company, plunked down $220 million to acquire medical device company Myoscience and its non-opioid pain treatment system iovera.
For Biogen, the acquisition brings Nightstar’s lead asset, NSR-REP1, a treatment for treatment of choroideremia (CHM), a rare and degenerative, X-linked inherited retinal disorder that leads to blindness, into its pipeline.
Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.
Topping an offer from Billerica, Massachusetts-based company Entegris, Darmstadt, Germany-based Merck KGaA offered an unsolicited $5.9 billion to acquire Versum Materials.
Shares of Bristol-Myers Squibb took a hit Wednesday after two large stakeholders in the company objected to the pending acquisition of Celgene. Wellington and Starboard Value have both publicly voiced opposition to the deal.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.
PRESS RELEASES